JP2010519311A - 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 - Google Patents

長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 Download PDF

Info

Publication number
JP2010519311A
JP2010519311A JP2009550992A JP2009550992A JP2010519311A JP 2010519311 A JP2010519311 A JP 2010519311A JP 2009550992 A JP2009550992 A JP 2009550992A JP 2009550992 A JP2009550992 A JP 2009550992A JP 2010519311 A JP2010519311 A JP 2010519311A
Authority
JP
Japan
Prior art keywords
acid
dpan
epimer
oil
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009550992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519311A5 (https=
Inventor
リンダ アーターバーン
ウィリアム バークレー
ビンディ ダンギ
ジェームズ フラット
ジャン リー
ダット ヴィンジャモーリ
エルスウィク メリー バン
Original Assignee
マーテック バイオサイエンシーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーテック バイオサイエンシーズ コーポレーション filed Critical マーテック バイオサイエンシーズ コーポレーション
Publication of JP2010519311A publication Critical patent/JP2010519311A/ja
Publication of JP2010519311A5 publication Critical patent/JP2010519311A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009550992A 2007-02-20 2008-02-20 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法 Pending JP2010519311A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89070107P 2007-02-20 2007-02-20
PCT/US2008/054456 WO2008103753A2 (en) 2007-02-20 2008-02-20 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2010519311A true JP2010519311A (ja) 2010-06-03
JP2010519311A5 JP2010519311A5 (https=) 2011-04-07

Family

ID=39710725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009550992A Pending JP2010519311A (ja) 2007-02-20 2008-02-20 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法

Country Status (5)

Country Link
US (1) US20110190389A1 (https=)
EP (1) EP2120920A4 (https=)
JP (1) JP2010519311A (https=)
CN (1) CN101663031A (https=)
WO (1) WO2008103753A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510517A (ja) * 2012-02-15 2015-04-09 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
JP2015140323A (ja) * 2014-01-29 2015-08-03 岩手県 Ｐｐａｒ活性化剤
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2022554152A (ja) * 2019-10-25 2022-12-28 ヌシード ニュートリショナル ユーエス インク． 濃縮多価不飽和脂肪酸組成物
WO2023090313A1 (ja) * 2021-11-16 2023-05-25 京都府公立大学法人 摂食量亢進用及び／又は食欲不振改善用組成物並びに一過性受容器電位アンキリン１を活性化するための組成物
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening
US12447117B2 (en) 2018-10-24 2025-10-21 Amorepacific Corporation Composition and method of enhancing skin barrier using the same

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
EP2344441B1 (en) * 2008-09-16 2016-02-17 The Brigham And Women's Hospital Inc. 7,14-dihydroxy-docosahexaenoic acid compounds
WO2010095706A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
FR2942964B1 (fr) * 2009-03-16 2012-08-17 Arkopharma Laboratoires Stimulateur metabolique des ppaps a base d'esters d'acides gras libres insatures, composition huileuse et complement alimentaire les contenant
EP2283839A1 (en) * 2009-06-30 2011-02-16 Institut National des Sciences Appliquées de Lyon Polyunsaturated hydroxylated molecule having an eze geometry and its use in therapy
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
HK1198515A1 (en) * 2011-07-21 2015-05-15 Dsm Ip Assets B.V. Fatty acid compositions
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
EP2760433B1 (en) * 2011-09-29 2023-05-31 PLx Opco Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
WO2013116753A1 (en) * 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US20170000752A1 (en) * 2014-01-24 2017-01-05 Kyoto University Anti-inflammatory agent containing rare fatty acid
US11135228B2 (en) * 2014-10-08 2021-10-05 The Brigham And Women's Hospital, Inc. Cysteinyl-proresolving mediators that promote resolution of infection and organ protection
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
HK1256301A1 (zh) * 2015-07-20 2019-09-20 The Brigham And Women's Hospital, Inc. 提高阿托伐他汀和清除感染的新的 13 系列消退素的说明
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
WO2017059451A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
WO2017208173A1 (en) * 2016-06-01 2017-12-07 National Research Council Of Canada Winter aconite fatty acid elongase and uses thereof in the production of fatty acids
EP3792351A4 (en) 2018-04-16 2022-01-19 Korea Research Institute of Bioscience and Biotechnology Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
EP4091672A4 (en) * 2020-02-18 2024-03-20 National University Corporation Hokkaido University STABLE BIOISOSTER OF RESOLVIN E2
CN114354785B (zh) * 2021-12-22 2023-06-27 中国农业科学院油料作物研究所 一种基于保留指数结合化学衍生化质谱特征二级碎片的氧脂素综合定性方法
WO2024108603A1 (zh) * 2022-11-25 2024-05-30 中国科学院深圳先进技术研究院 基于粪便代谢物的神经退行性疾病标志物及其应用
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné
CN121027545B (zh) * 2025-10-31 2026-02-03 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的负离子代谢标志物、产品及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
CN1109543C (zh) * 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
CA2362515C (en) * 1999-03-04 2008-07-15 Suntory Limited Utilization of material containing docosapentaenoic acid
JP4474082B2 (ja) * 1999-07-07 2010-06-02 キリン協和フーズ株式会社 水酸化脂肪酸およびδ−ラクトン類の製造方法
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002029018A2 (en) * 2000-10-06 2002-04-11 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
US7527935B2 (en) * 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
AU2003260687A1 (en) * 2002-04-01 2003-10-20 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
FR2843124B1 (fr) * 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US20040166130A1 (en) * 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510517A (ja) * 2012-02-15 2015-04-09 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2019163265A (ja) * 2013-05-30 2019-09-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
US11667598B2 (en) 2013-05-30 2023-06-06 The Brigham & Women's Hospital Inc. N-3 immunoresolvents: structures and actions
JP2015140323A (ja) * 2014-01-29 2015-08-03 岩手県 Ｐｐａｒ活性化剤
US12447117B2 (en) 2018-10-24 2025-10-21 Amorepacific Corporation Composition and method of enhancing skin barrier using the same
JP2022554152A (ja) * 2019-10-25 2022-12-28 ヌシード ニュートリショナル ユーエス インク． 濃縮多価不飽和脂肪酸組成物
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening
WO2023090313A1 (ja) * 2021-11-16 2023-05-25 京都府公立大学法人 摂食量亢進用及び／又は食欲不振改善用組成物並びに一過性受容器電位アンキリン１を活性化するための組成物

Also Published As

Publication number Publication date
EP2120920A2 (en) 2009-11-25
CN101663031A (zh) 2010-03-03
WO2008103753A3 (en) 2008-11-27
US20110190389A1 (en) 2011-08-04
EP2120920A4 (en) 2011-06-15
WO2008103753A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
JP2010519311A (ja) 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
CN101102988B (zh) 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US7893106B2 (en) Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
EP1296923B3 (en) Aspirin-triggered lipid mediators
US20090320148A1 (en) Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
JP2010519311A5 (https=)
AU2014358123B2 (en) Dihomo-gamma-linolenic acid-containing microbial oil and dihomo-gamma-linolenic acid-containing microbial biomass
BRPI0311916B1 (pt) processo para a produção de um óleo microbiano compreendendo ácido araquidônico
JP7242769B2 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
AU2011253846A1 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
NO348700B1 (en) Cetoleic acid composition
US20110027841A1 (en) Method for preparation of oxylipins
HK1105948B (en) Aspirin triggered lipid mediators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110218

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120705